Morphologic and molecular tumor characteristics before imatinib therapy (per protocol)
| Patient ID | Tumor type | COL1A1–PDGFB | Localization (tissue layers involved) | CD34 | S100 | Vascularization | Hemorrhages | Cellular/nuclear pleomorphism | Ki67 | Mitoses |
|---|---|---|---|---|---|---|---|---|---|---|
| ADO-01 | DFSP | NE | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | Several | None/none | 5% | None |
| ADO-02 | DFSP | NE | Dermis + subcutis + sceletal muscles | Positive (homogeneous) | Negative | High | None | None/moderate | ND | None |
| ADO-03 | DFSP | ND | Subcutis | Positive (heterogeneous) | Negative | Low | None | None/moderate–high | ND | Several |
| ADO-04 | DFSP-FS | Positive (RT-PCR + sequencing, FISH) | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | None | Low–moderate/none | 6% | Sporadic |
| ADO-05 | DFSP | Positive (RT-PCR + sequencing) | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | None | None/none | 2% | None |
| ADO-06 | DFSP, myxoid type | Positive (RT-PCR + sequencing, FISH) | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | None | Low/none | 3% | None |
| ADO-07 | DFSP-FS, pigmented type | Positive (RT-PCR + sequencing, FISH) | Dermis + subcutis | Positive (heterogeneous) | Positive (heterogeneous) | High | None | Moderate/moderate–high | ND | Sporadic |
| ADO-09 | DFSP, pigmented-type | ND | Dermis + subcutis | Positive (homogeneous) | Negative | Low | None | None/none | ND | None |
| ADO-10 | DFSP | Negative (RT-PCR + sequencing) | Dermis + subcutis | Positive (homogeneous) | ND | Moderate | None | None/none | 4% | None |
| ADO-11 | DFSP | Positive (RT-PCR + sequencing) | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | None | None/none | 4% | None |
| ADO-12 | DFSP | ND | Dermis + subcutis + deep soft tissue + bone | Positive–negative (heterogeneous) | Negative | High | Numerous | None/none | 5% | None |
| ADO-13 | DFSP | Negative (FISH) | Dermis + subcutis | Positive (homogeneous) | Negative | Moderate | None | Low/none | 8% | Sporadic |
| ADO-15 | DFSP | NE | Dermis + subcutis | Positive (homogeneous) | Negative | Low | None | Moderate/none | 2% | None |
| ADO-16 | DFSP | Negative (RT-PCR + sequencing) | Dermis + subcutis | Positive (homogeneous) | ND | Moderate | None | Low/none | 2% | Several |
NOTE: Morphologic and molecular tumor characteristics as analyzed in the per protocol population, for details see Patients and Methods.
Abbreviations: ND, not done; NE, not evaluable.